✦ LIBER ✦

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

✍ Scribed by Neal Weinreb; John Taylor; Timothy Cox; John Yee; Stephan vom Dahl

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 218 KB
Volume: 83
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.21280

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Guidance on the use of miglustat for tre

Guidance on the use of miglustat for treating patients with type 1 Gaucher disease

✍ Neal J. Weinreb; John A. Barranger; Joel Charrow; Gregory A. Grabowski; Henry J. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 1 views

Compound heterozygosity for a disease-ca

Compound heterozygosity for a disease-causing G1489D and disease-modifying G530S substitution inCOL5A1 of a patient with the classical type of Ehlers-Danlos syndrome: An explanation of intrafamilial variability?

✍ Giunta, Cecilia; Steinmann, Beat 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

The classical type of Ehlers-Danlos syndrome (EDS) is an autosomal dominant connective tissue disorder characterized by skin hyperelasticity, tissue fragility, and joint hypermobility. We investigated the molecular defect of EDS in a three-generation family. Cultured dermal fibroblasts from the prop

Homozygous state for a new single bp-del

Homozygous state for a new single bp-deletion (g.787delA) in exon 5 of the glucose-6-phosphatase gene in a patient with early onset of glycogen storage disease type 1a

✍ M. Linnebank; B. Rapp; A. Homberger; C. Winter; T. Marquardt; U. Künzel; H.G. Ko 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 10 KB 👁 2 views